1) MERFISH 2.0: Higher Resolution, Greater Discovery
Higher sensitivity, refined probe design, and broader sample compatibility (including archival FFPE), fully compatible with both the MERSCOPE® and MERSCOPE Ultra™ platforms. Thank you for the enthusiastic adoption, as you are now demonstrating impact across oncology, neuroscience, and immunology. We also expanded Vizgen Lab Services to include MERFISH 2.0™ service offerings supported by STARVUE™ analysis, making it easier for teams to access spatial transcriptomics without capital or staffing constraints.
2) ADC-ready Panels: Biomarkers that Speed Translation
We enhanced OmniVUE™ panels with validated ADC biomarkers to help teams link target discovery with the translational insights needed to evaluate safety, specificity, and therapeutic potential. The expansion of our Certified Service Partner (CSP) Program, including pathology-grade proteomics, further broadened access to these tools across global research centers.
3) A Shorter Path from Slides to Insights
Our partnership with Hamamatsu Photonics integrates automated mIF imaging with Vizgen’s assays, streamlining multiplex workflows for biomarker development. This collaboration shortens validation timelines and removes common bottlenecks in multiplex assay development, helping teams get to answers faster.
4) Proof Points in Peer Review
Vizgen’s platforms now rank among the most cited spatial biology tools in top-tier journals, and we’re honored to be named once again GEN’s Top Private Spatial Biology Company. This year, critical neurological insights emerged in Nature publications. Highlights include a Nature Neuroscience study that used MERSCOPE to map aging-related white matter changes at single-cell resolution, demonstrating how high-fidelity spatial data changes the questions researchers can ask. A second study, published in the October issue of Nature, revealed new insights into neurodevelopment and Down syndrome using the MERSCOPE platform. Our STARVUE™ AI-enhanced analysis suite was recognized as one of The Scientist’s Top 10 Innovations of 2024, reflecting the strength of this integrated platform.
5) One Team, Stronger Together
Since merging with Ultivue last year, we’ve continued unifying transcriptomics, proteomics, and AI-driven analysis. Our commercial team expanded with the addition of Chad Brown as Chief Commercial Officer, solidifying our commercial organization to support you end-to-end, when and where you need us. We also welcomed Christian Uhrich of M Ventures to our Board of Directors to help guide Vizgen’s long-term strategic growth.
